Boehringer Ingelheim cancels planned German investments amid austerity concerns

Boehringer Ingelheim is canceling 900 million euros in planned investments in Germany, a move affecting new projects between 2027 and 2030. The pharmaceutical company confirmed the decision, which was first reported by Handelsblatt. The primary driver behind this cancellation is the German federal government's austerity measures within the healthcare sector, specifically anticipated increases in mandatory and manufacturer discounts. Boehringer Ingelheim argues these measures undermine the predictability crucial for an industry characterized by long development cycles.

The company also highlighted a general decline in the operating environment for the pharmaceutical industry in both Europe and Germany. In contrast, markets such as the United States and China are becoming increasingly attractive for investment. Médard Schoenmaeckers, head of Boehringer Ingelheim in Germany, told Handelsblatt that "the next innovation will, as things stand, not go to Germany." He added that the company must keep pace with developments in the US and Asia.

“

the next innovation will, as things stand, not go to Germany.

This decision occurs amidst intensifying global competition. The US pharmaceutical sector faces significant political pressure, yet major pharmaceutical corporations are heavily investing in production and research there. Boehringer itself plans to invest approximately 10 billion euros in the United States by 2028. Meanwhile, countries like China and India are advancing in new drug development.

US pharmaceutical giant Eli Lilly is also significantly reducing its investments in Germany. CEO Dave Ricks informed Handelsblatt that the originally planned 2.3 billion euros for a plant in Rhineland-Palatinate will be halved. The investments withdrawn from Germany are likely to be redirected to Pennsylvania in the US or a new, yet-to-be-built site. Ricks also cited the German government's planned austerity measures as a reason for this restructuring, noting that "Germany is falling to last place in Europe in supporting our industry."

“

Germany is falling to last place in Europe in supporting our industry.